65 completed, 23 terminated, 9 recruiting, 4 active not recruiting. 59 Phase 2, 34 Phase 3, 17 Phase 1, 1 Early Phase 1, 1 Phase 4.
Follow canakinumab: new trials by email Literature Review of canakinumab trials Research Report on canakinumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis CANAKINUMAB (ILARIS®), Saline (NaCl 0,9 %) (placebo) - Vascular Inflammation, ASCVD | Phase 2 | Recruiting | Massachusetts General Hospital | 120 | 2026-03-24 | 2026-10-15 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| IL1 Inhibition in FOP Anti-IL1 Therapy - Fibrodysplasia Ossificans Progressiva (FOP) | Recruiting | University of California, San Francisco | 11 | 2025-04-01 | 2026-08-06 | |
| Ilaris NIS in Korea Ilaris - Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS) | Recruiting | Novartis Pharmaceuticals | 25 | 2025-03-29 | 2026-05-19 | |
| Evaluation of Canakinumab in High-Risk Former-Smokers Biospecimen Collection, Bronchoscopy, Canakinumab - Cigarette Smoking-Related Carcinoma, Lung Carcinoma | Phase 2 | Completed | Peter Shields | 41 | 2024-03-11 | 2026-07-07 |
| An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's Disease GNR-086, Ilaris® - Still's Disease Adult Onset | Phase 3 | Completed | AO GENERIUM | 118 | 2023-12-12 | 2025-08-17 |
| A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer Canakinumab, Tislelizumab, Nab-Paclitaxel - Pancreatic Cancer | Phase 1 | Active not recruiting | NYU Langone Health | 9 | 2023-07-14 | 2026-03-30 |
| Canakinumab for the Treatment of Postprandial Hypoglycemia Canakinumab, Placebo (0.9% NaCl) - Postprandial Hypoglycemia | Phase 3 | Recruiting | University Hospital, Basel, Switzerland | 56 | 2023-04-17 | 2025-01-29 |
| Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Canakinumab - Clonal Cytopenia of Undetermined Significance | Phase 2 | Recruiting | Uma Borate | 110 | 2023-02-06 | 2026-01-02 |
| Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Squaric Acid Dibutyl Ester, Known patch test allergens, Dupilumab - Skin Inflammation, Allergic Contact Dermatitis | Phase 2 / Phase 3 | Active not recruiting | Wei-Che Ko | 45 | 2022-11-15 | 2026-06-09 |
| A Safety, Pharmacokinetics and Pharmacodynamics Study of GNR-086 and Ilaris® in Healthy Volunteers GNR-086, Ilaris® - Healthy Volunteers | Phase 1 | Completed | AO GENERIUM | 105 | 2022-09-06 | 2024-07-01 |
| Study of Canakinumab in Patients With Myelofibrosis Canakinumab - Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | Phase 2 | Active not recruiting | John Mascarenhas | 14 | 2022-08-02 | 2026-05-07 |
| Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients Canakinumab Injection - Anemia, Myelodysplastic Syndromes | Phase 2 | Terminated | University of Leipzig | 10 | 2022-04-26 | 2024-05-06 |
| A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer Canakinumab, Placebo - Lung Cancer | Phase 3 | Terminated | Mario Negri Institute for Pharmacological Research | 350 | 2022-02-03 | 2023-02-13 |
| COVID-19 VaccinE Response in Rheumatology Patients Upadacitinib, Abatacept, Secukinumab - Rheumatoid Arthritis, Psoriatic Arthritis | Phase 4 | Completed | Jeffrey Curtis | 841 | 2021-11-15 | 2025-05-02 |
| Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease Canakinumab, Placebo - Mild Cognitive Impairment, Alzheimer Disease | Phase 2 | Terminated | Novartis Pharmaceuticals | 34 | 2021-10-28 | 2025-10-16 |
| A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA) canakinumab, LNA043, Placebo to canakinumab - Knee Osteoarthritis | Phase 2 | Terminated | Novartis Pharmaceuticals | 23 | 2021-08-27 | 2025-10-24 |
| Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial Canakinumab, Quality-of-Life Assessment - Lung Carcinoma, Stage I Lung Cancer AJCC v8 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 50 | 2021-07-20 | 2026-06-12 |
| Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS MBG453, NIS793, canakinumab - Myelodysplastic Syndromes | Phase 1 | Terminated | Novartis Pharmaceuticals | 33 | 2021-06-18 | 2025-10-10 |
| A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer Canakinumab, Durvalumab, Radiation therapy - Non-small Cell Lung Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 41 | 2021-05-21 | 2026-07-08 |
Showing 20 of 109. Sign in to see all of them.
Arthritis, Juvenile (10) · Cryopyrin-Associated Periodic Syndromes (10) · Arthritis, Rheumatoid (8) · Carcinoma, Non-Small-Cell Lung (7) · Gout (7) · Arthritis (6) · Arthritis, Gouty (6) · COVID-19 (6) · Diabetes Mellitus, Type 2 (5) · Multiple Pterygium Syndrome, Autosomal Dominant (5) · Myelodysplastic Syndromes (5) · Arthralgia (4) · Coronavirus Infections (4) · Inflammation (4) · Lung Neoplasms (4)
Novartis Pharmaceuticals (54) · Novartis (17) · Charite University, Berlin, Germany (3) · University Hospital, Basel, Switzerland (3) · AO GENERIUM (2) · M.D. Anderson Cancer Center (2) · NYU Langone Health (2) · University of Zurich (2) · AUSL Romagna Rimini (1) · Children's National Research Institute (1) · Columbia University (1) · Duke University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Imperial College London (1) · Jeffrey Curtis (1)
United States (64) · Germany (43) · Canada (28) · Spain (27) · United Kingdom (27) · Italy (24) · Belgium (23) · Switzerland (22) · France (21) · Netherlands (20) · Russia (20) · Turkey (Türkiye) (19) · Poland (15) · Israel (14) · Hungary (13)
Oksana A. Markova, MD (2) · Andrea De Censi (1) · Anna Berkenbilt (1) · Anna Simon, MD PhD (1) · Anne Sophie Kubasch, Dr. (1) · Chi Hornik (1) · Christopher Spurney (1) · David A Sallman, MD (1) · David Conen, Prof. (1) · Edward Hsiao, MD, PhD (1)
PMID 30269054, PMID 24122883, PMID 26314396, PMID 23252526, PMID 28115015, PMID 31161734, PMID 18534016, PMID 19494217, PMID 20533546, PMID 21356079, PMID 21439048, PMID 21540198, PMID 21736751, PMID 21859692, PMID 21982649, PMID 22152723, PMID 22901459, PMID 23087179, PMID 23129601, PMID 23380020, PMID 23562090, PMID 24075453, PMID 24906637, PMID 25049046, PMID 25240532, PMID 26337145, PMID 26546248, PMID 26589963, PMID 27269295, PMID 27474763, PMID 27737744, PMID 28482144, PMID 28845751, PMID 28855077, PMID 29146124, PMID 29544870, PMID 29768139, PMID 29793629, PMID 30165610, PMID 30242335, PMID 30586730, PMID 31277561, PMID 31504417, PMID 31884854, PMID 32203978, PMID 32552266, PMID 32744862, PMID 32783351, PMID 32827729, PMID 33004131
2018 (5), 2009 (4), 2016 (2), 2014 (1), 2017 (1), 2019 (1), R01AR083628 (1), UC4DK097835 (1)